Association of anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis
Authors' conclusion
Anti-TPM4 autoantibodies are detected frequently in children with JDM and are novel myositis-associated autoantibodies. Their presence correlates with vasculopathic and other cutaneous manifestations of JDM that may be indicative of more refractory disease.
Study context
- Population
- Children with JDM, polyarticular JIA and healthy children
- Participants
- 63 / 50 / 40
- Exposure
- JDM vs polyarticular JIA (pJIA) vs healthy children (HC); JDM with vs without anti-TPM4 autoantibodies
- JDMn = 63
- pJIAn = 50
- HCn = 40reference
- Outcome
- Presence of anti-TPM4 autoantibodies (ELISA) and correlation with clinical features of JDM
Methodological detailsELISA, Western blotting, TPM4 protein expression in cultured normal human dermal microvascular endothelial cells (ECs) shown by Western blotting
- ELISA
- Western blotting
- TPM4 protein expression in cultured normal human dermal microvascular ECs shown by Western blotting
Main finding
As reported in the abstract
Anti-TPM4 autoantibodies detected in plasma
JDM vs pJIA: P < 0.0001 · JDM vs HC: P < 0.0001
Observational data: associations, not effects.
Further findings
Clinical features associated with anti-TPM4 autoantibodies in JDM
- Cutaneous ulcers (53%)
- P = 0.02
- Shawl sign rash (47%)
- P = 0.03
- Mucous membrane lesions (84%)
- P = 0.04
- Subcutaneous edema (42%)
- P < 0.05
Treatment associated with anti-TPM4 autoantibodies in JDM
- Use of intravenous steroids and IVIG therapy (significant correlation)
- both P = 0.01
- Higher total number of medications received with anti-TPM4 autoantibodies
- P = 0.02
Original publication
Association of anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis. Rheumatology (Oxford). Published 5 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →